PubMed Health⌕ Search

Biomedical subjects

T C Welbourne

Publications and source records attributed to T C Welbourne.

At least 19 recordsLinked to original sources
PubMed2003

Content of ileal EAAC1 and hepatic GLT-1 high-affinity glutamate transporters is increased in growing vs. nongrowing lambs, paralleling increased tissue D- and L-glutamate, plasma glutamine, and alanine concentrations.

Glutamate is a central metabolite for whole-animal energy and N metabolism. This study tested the hypothesis that ileal epithelium, liver, and kidney content of system X-(AG) glutamate transporters EAAC1 and GLT-1 would be up-regulated to support growth of wethers (30 +/- 1.2 kg) fed a forage-based diet for at least 14 d to gain (2.0 x NEm; n = 9) vs. maintain (1.2 x NEm; n = 9) BW. We have previously demonstrated that two high-affinity glutamate transporters (EAAC1, GLT-1) are expressed by these extensive glutamate metabolizing epithelial tissues. Wethers fed at 2.0 x NEm gained (P < 0.001; 0.26 kg/d) BW, whereas those fed 1.2 x NEm did not. Although plasma concentrations (microM) of glucose and L- or D-glutamate did not differ, plasma glutamine (precursor of glutamate) and alanine concentrations (transamination product of glutamate) were 28% (P < 0.007) and 22% (P < 0.072) greater for growing lambs than nongrowing lambs. In tissues, the concentration of L-glutamate in ileum epithelia and D-glutamate of liver was 49% (P < 0.015) and 181% (P < 0.042) greater, respectively, in growing vs. nongrowing animals, whereas concentrations of glutamate isoforms did not differ in kidney. Paralleling these increased amino acid concentrations, ileal epithelium contained 313% more (P < 0.038) EAAC1 protein and liver contained 240% more (P < 0.001) GLT-1 protein, whereas kidney transporter content did not differ between growing and nongrowing wethers. In contrast to increased EAAC1 and GLT-1 protein content in ileal and liver tissue of growing lambs, messenger RNA levels did not differ. These results indicate that the increased capacity for high-affinity glutamate uptake in growing vs. nongrowing lambs is achieved through increased expression of EAAC1 by ileal epithelium and GLT1 by liver, which parallel increased tissue concentrations of glutamate and plasma concentrations of two major interorgan N carriers, glutamine and alanine.

Alanine↗
PubMed2000

Advanced glycation end products: a Nephrologist's perspective.

Advanced glycation end products (AGEs) are a heterogeneous group of molecules that accumulate in plasma and tissues with advancing age, diabetes, and renal failure. There is emerging evidence that AGEs are potential uremic toxins and may have a role in the pathogenesis of vascular and renal complications associated with diabetes and aging. AGEs are formed when a carbonyl of a reducing sugar condenses with a reactive amino group in target protein. These toxic molecules interact with specific receptors and elicit pleiotropic responses. AGEs accelerate atherosclerosis through cross-linking of proteins, modification of matrix components, platelet aggregation, defective vascular relaxation, and abnormal lipoprotein metabolism. In vivo and in vitro studies indicate that AGEs have a vital role in the pathogenesis of diabetic nephropathy and the progression of renal failure. The complications of normal aging, such as loss of renal function, Alzheimer's disease, skin changes, and cataracts, may also be mediated by progressive glycation of long-lived proteins. AGEs accumulate in renal failure as a result of decreased excretion and increased generation resulting from oxidative and carbonyl stress of uremia. AGE-modified beta(2)-microglobulin is the principal pathogenic component of dialysis-related amyloidosis in patients undergoing dialysis. Available dialytic modalities are not capable of normalizing AGE levels in patients with end-stage renal disease. A number of reports indicated that restoration of euglycemia with islet-cell transplantation normalized and prevented further glycosylation of proteins. Aminoguanidine (AGN), a nucleophilic compound, not only decreases the formation of AGEs but also inhibits their action. A number of studies have shown that treatment with AGN improves neuropathy and delays the onset of retinopathy and nephropathy. N-Phenacylthiazolium bromide is a prototype AGE cross-link breaker that reacts with and can cleave covalent AGE-derived protein cross-links. Thus, there is an exciting possibility that the complications of diabetes, uremia, and aging may be prevented with these novel agents.

Aging↗
PubMed2000

Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.

BACKGROUND: Renal complications of long-term, poorly controlled type 2 diabetes mellitus include glomerulosclerosis and interstitial fibrosis. The onset and progression of these complications are influenced by underlying pathophysiologies such as hyperglycemia, hypertriglyceridemia, and hypercholesterolemia. Troglitazone, a thiazolidinedione, has been shown to ameliorate these metabolic defects. However, it was not known whether therapeutic intervention with troglitazone would prevent the onset and progression of glomerulosclerosis. METHODS: Sixty male ZDF/Gmitrade mark rats and 30 age-matched Zucker lean rats were in the study. The ZDF/Gmitrade mark rats were divided into two groups, one in which blood glucose levels were uncontrolled (30 animals) and another (30) in which blood glucose was controlled via dietary administration of troglitazone. Ten animals from each group were sacrificed at one, three, and six months into the study. The kidneys were harvested and processed for immunostaining with BM-CSPG, a marker for mesangial matrix. Images of 200 glomeruli per animal were captured using digital imaging microscopy, and the index of mesangial expansion (total area mesangium/total area of tuft) per glomerular section was measured. RESULTS: The administration of troglitazone ameliorated the metabolic defects associated with type 2 diabetes mellitus. Moreover, the glomeruli from tissue sections of animals given troglitazone showed no mesangial expansion when compared with normoglycemic control animals, whereas the uncontrolled diabetic animals showed significant mesangial expansion at all time intervals. CONCLUSIONS: Therapeutic intervention with the thiazolidinedione troglitazone halts the early onset and progression of mesangial expansion in the ZDF/Gmitrade mark rat, preventing the development of glomerulosclerosis in this animal model of type 2 diabetes mellitus.

Animals↗
PubMed1999

Intracameral muramyl dipeptide-induced paracellular permeability associated with decreased glutamate transporter and gamma -glutamyltranspeptidase activities.

Muramyl dipeptide (MDP) (N -acetylmuramyl- L -alanyl- D - isoglutamine) was injected intracamerally to test if MDP applied to the aqueous side of the blood-aqueous barrier would increase paracellular permeability in association with diminished uptake of glutamate. The symptoms of anterior uveitis, i.e., increase in vascular dilatation, could be detected as early as 30 min post MDP injection while aqueous protein concentration did not increase at this time suggesting an initial dissociation between the circulatory and epithelial barrier responses. However, at 45 min, the aqueous protein concentration increased 10-fold (201+/-174 to 2094+/-1835 micrograms ml-1;P<0.001) rising progressively to 20-fold above the control eye at 60 min post injection (254+/-194 vs. 5038+/-2514 micrograms ml-1;P<0.001). Epithelial cell barrier paracellular permeability increased at 45 min as evidenced by the enhanced efflux of radiolabelled L -glucose out of the aqueous (8% and 13% faster than control at 45 and 60 min post MDP injection, respectively), coinciding with the accelerated protein influx. A near 50% reduction in efflux of both radiolabelled glutamate and D -aspartate was consistent with reduced glutamate uptake by the transport system X-AG. In addition, a 24% decline in aqueous glutamate, but not aspartate, was detected in the aqueous of the MDP-treated eyes in association with a 54% decrease in iris/ciliary body gamma-glutamyltranspeptidase activity consistent with reduced de novo glutamate formation from glutamine. The aqueous of MDP injected eyes also had 6-fold and 34-fold higher prostaglandin E2and F2alphaconcentrations, respectively (P</=0.03) as well as reduced AH bicarbonate concentration. These results suggest that increased paracellular permeability is associated with diminished gamma-glutamyltranspepidase-mediated glutamate production, X-AGtransport activity, and cellular acidosis in the MDP-induced prostaglandin-mediated inflammation.

ATP-Binding Cassette Transporters↗
PubMed1999

Introduction: glutamate transport, metabolism, and physiological responses.

The material covered in this set of articles was originally presented at Experimental Biology '98, in San Francisco, CA, on April 20, 1998. Here, the participants recount important elements of current research on the role of glutamate transporter activity in cellular signaling, metabolism, and organ function. W. A. Fairman and S. G. Amara discuss the five subtypes of human excitatory amino acid transporters, with emphasis on the EAAT4 subtype. M. A. Hediger discusses the expression and action of EAAC1 subtype of the human excitatory amino acid transporter. I. Nissim provides an overview of the significant role of pH in regulating Gln/Glu metabolism in the kidney, liver, and brain. J. D. McGivan and B. Nicholson describe some characteristics of glutamate transport regulation with regard to a specific experimental model of the bovine renal epithelial cell line NBL-1. Finally, T. C. Welbourne and J. C. Matthews introduce the "functional unit" concept of glutamate transport and how this relates to both glutamine metabolism and paracellular permeability.

ATP-Binding Cassette Transporters↗
PubMed1999

Glutamate transport and renal function.

Brush border gamma-glutamyltransferase-glutaminase activity and the high-affinity glutamate transporter EAAC1 function as a unit in generating and transporting extracellular glutamate into proximal tubules as a signal that modulates intracellular glutamine/glutamate metabolism, paracellular permeability, and urinary acidification. The reported presence of a second glutamate transporter, GLT1, on the antiluminal tubule surface points to specific functional roles for each subtype in physiological and pathophysiological processes.

ATP-Binding Cassette Transporters↗
PubMed1998

Plasma-to-lumen clearance of para-aminohippurate can replace 51Cr EDTA clearance in the evaluation of intestinal mucosal injury.

Intestinal mucosal injury of various degrees occurs in many clinical situations and is initially evidenced by altered mucosal permeability. The latter may be assessed in animal models by determination of plasma-to-intestinal lumen clearance of specific molecules, usually chromated 51Cr EDTA. The purpose of this study was to evaluate the usage of para-aminohippurate (PHA) as a substitute for the commonly used radioactive material, i.e., 51Cr-EDTA, in the evaluation of intestinal mucosal injury. An isolated loop of ileum was created in rats and constantly perfused with warmed normal saline. Both renal pedicles were ligated. Either 51Cr-EDTA (18.5 Bq/kg) or PAH (58 mg/kg) was injected i.v. Fifteen-minute intestinal ischemia was produced by clamping the superior mesenteric artery immediately after the end of an equilibration period. The perfusate was collected for 10 min prior to the initiation of intestinal ischemia, during the last 10 min of ischemia, and during the following three 10-min periods of reperfusion. Blood samples were collected at the end of each collection period for the determination of either PAH or 51Cr-EDTA concentrations and the calculation of either PHA or 51Cr-EDTA plasma-to-lumen clearances. PAH and 51Cr-EDTA plasma-to-lumen clearances followed the same pattern in all five assessed periods with no statistical difference between the two. PAH plasma-to-lumen clearance is a feasible, reliable, and inexpensive method for the evaluation of ischemia/reperfusion injury to the intestinal mucosa. It can safely replace the commonly used method in animal models that utilizes radioactive materials such as 51Cr-EDTA.

Animals↗
PubMed1998

Glutamate transport and cellular glutamine metabolism: regulation in LLC-PK1 vs. LLC-PK1-F+ cell lines.

The glutamate (Glu) transporter may modulate cellular glutamine (Gln) metabolism by regulating both the rates of hydrolysis and subsequent conversion of Glu to alpha-ketoglutarate and NH+4. By delivering Glu, a competitive inhibitor of Gln for the phosphate-dependent glutaminase (PDG) as well as an acid-load activator of glutamate dehydrogenase (GDH) flux, the transporter may effectively substitute extracellularly generated Glu from the gamma-glutamyltransferase for that derived intracellularly from Gln. We tested this hypothesis in two closely related porcine kidney cell lines, LLC-PK1 and LLC-PK1-F+, the latter selected to grow in the absence of glucose, relying on Gln as their sole energy source. Both cell lines exhibited PDG suppression as the result of Glu uptake while disrupting the extracellular L-Glu uptake, with D-aspartate-accelerated intracellular Glu formation coupled primarily to the ammoniagenic pathway (GDH). Conversely, enhancing the extracellular Glu formation with p-aminohippurate and Glu uptake suppressed intracellular Gln hydrolysis while NH+4 formation from Glu increased. Thus these results are consistent with the transporter's dual role in modulating both PDG and GDH flux. Interestingly, PDG flux was actually higher in the Gln-adapted LLC-PK1-F+ cell line because of a two- to threefold enhancement in Gln uptake despite greater Glu uptake than in the parental LLC-PK1 cells, revealing the importance of both Glu and Gln transport in the modulation of PDG flux. Nevertheless, when studied at physiological Gln concentration, PDG flux falls under tight Glu transporter control as Gln uptake decreases, suggesting that cellular Gln metabolism may indeed be under Glu transporter control in vivo.

ATP-Binding Cassette Transporters↗
PubMed1998

Glutamate transport asymmetry in renal glutamine metabolism.

D-Glutamate (Glu) was previously shown to block L-Glu uptake and accelerate glutaminase flux in cultured kidney cells [Welbourne, T. C., and D. Chevalier. Am. J. Physiol. 272 (Endocrinol. Metab. 35): E367-E370, 1997]. To test whether D-Glu would be taken up by the intact functioning kidney and effect the same response in vivo, male Sprague-Dawley rats were infused with D-Glu (2.6 mumol/min), and renal uptake of D- and L-Glu was determined from chemical and radiolabeled arteriovenous Glu concentration differences times renal plasma flow. The amount removed was then compared with that amount filtered to obtain the antiluminal contribution. In the controls, L-Glu uptake measured as net removal was 33% of the arterial L-Glu load and not different from that filtered, 27%; however, the unidirectional uptake was actually 58% of the arterial load, indicating that antiluminal uptake contributes at least half to the overall Glu consumption. Surprisingly, the kidneys showed a more avid removal of D-Glu, removing 73% of the arterial load, indicating uptake predominantly across the antiluminal cell surface. Furthermore, uptake of D-Glu was associated with a 55% reduction in L-Glu uptake, with the residual amount taken up equivalent to that filtered; D-Glu did not increase the excretion of the L-isomer. However, elevating plasma L-Glu concentration reduced uptake of the D-isomer, suggesting a shared antiluminal transporter. Thus there is an apparent asymmetrical distribution of the D-Glu transporter. Under these conditions, kidney cortex L-Glu content decreased 44%, whereas net glutamine (Gln) uptake increased sevenfold (170 +/- 89 to 1,311 +/- 219 nmol/min, P < 0.01) and unidirectional uptake nearly threefold (393 +/- 121 to 1,168 +/- 161 nmol/min, P < 0.05); this large Gln consumption was paralleled by an increase in ammonium production so that the ratio of production to consumption approaches 2, consistent with accelerated Gln deamidation and subsequent Glu deamination. These results point to a functional asymmetry (antiluminal vs. luminal) for Glu transporter activity, which potentially plays an important role in modulating Gln metabolism and renal function.

Animals↗
PubMed1997

Inhibition of glutamate uptake causes an acute increase in aqueous humor protein.

Inhibition of glutamate transport has been shown to increase paracellular permeability of epithelial cell monolayers in vitro. To determine if blocking glutamate transport would affect tissue permeability in vivo, D-aspartate (D-Asp; 300 nmol 30 microliters-1) (a non-toxic competitive inhibitor of glutamate transport) or a placebo was injected into the anterior chambers of the fellow eyes of 15 adult rabbits. [14C]-L-glucose and/or [125I]-rabbit albumin were included in the injection vehicle as aqueous humor (AH) outflow markers. The specific inhibition of glutamate uptake by D-Asp was indicated by a 15% increase in AH glutamate (174 +/- 9 nmol ml-1 to 205 +/- 13 nmol ml-1; P = 0.03) at 1-1.5 hr post injection. Also, the efflux of [14C]-L-glucose and [125I]-rabbit albumin from the AH of D-Asp injected eyes was increased 22% over the placebo-injected control eyes (P < or = 0.02). Concomitantly, the total protein concentration in the AH from D-Asp injected eyes (517 +/- 35 micrograms ml-1) was 19% greater (P < 0.02) than the protein concentration in AH from placebo-injected control eyes (420 +/- 36 micrograms ml-1). In additional studies, an irreversible inhibitor of glutamate transport, threo-beta-hydroxyaspartate (THA; 30 nmol 30 microliters-1), was shown to increase the efflux of [14C]-L-glucose (22%; P < 0.05) from the anterior chamber and increase AH protein concentrations by 29% (484 +/- 112 micrograms ml-1 in control AH versus 686 +/- 117 micrograms ml-1 in THA AH, P = 0.08) at 1 hr post intracameral injection. SDS-PAGE analysis of the AH associated the protein increase in the D-Asp and THA injected eyes but not placebo-injected control eyes with a detectable increase in a 66 kDa protein (aligns with serum albumin) and several lower molecular weight (23-35 kDa) AH proteins. The results found suggest that inhibition of glutamate transport from the AH acutely increases intraocular epithelial/endothelial paracellular permeability.

Alanine↗
PubMed1997

The role of growth hormone in substrate utilization.

Substrate fluxes in response to growth hormone administration depend on both the calorie as well as acid-base balance. Growth hormone's acidogenic action as a consequence of promoting fatty acid utilization yields protons required for driving hepatic glutamate efflux; effective uncoupling of nitrogenous precursors from ureagenesis and recycling as glutamate bound for the periphery appears dependent upon this mechanism. Subsequent peripheral retrieval of the salvaged glutamate requires insulin-like growth factor-1 (IGF-1) activated uptake and acid-base homoeostasis. In addition to this nitrogen sparing acidogenic effect, growth hormone is also basogenic in combination with IGF-1 and acting on the kidney as a target organ. Therefore acid-base and nitrogen homoeostasis are normally attuned to one another through the co-ordinated action of growth hormone/IGF-1 on substrate fluxes. However during starvation ketoacid production as the consequence of incomplete fatty acid oxidation and ketone excretion swamps the basogenic limb and full-blown metabolic acidosis prevails; under this condition growth hormone's effectiveness in sparing nitrogen for anabolic processes is curtailed as glutamate (emanating from the liver) and glutamine (derived from muscle proteolysis) are directed to the kidneys, supporting ammoniogenesis: nitrogen balance is now sacrificed for acid-base homoeostasis. Underlying this state is an intracellular acidosis that may contribute to insulin resistance and developing hyperglycaemia in response to growth hormone. In acute injury, an additional acid load contributed from muscle proteolysis and cytokines reinforces an intracellular acidosis that further blunts growth hormone responsiveness and suppresses coupled IGF-1 production. From this perspective growth hormone's acidogenic and basogenic actions should balance for an effective anabolic response during hypermetabolic catabolic illnesses.

Animals↗
PubMed1997

Glutamate transport and not cellular content modulates paracellular permeability in LLC-PK1-F+ cells.

Uptake of glutamate modulates two cellular processes: 1) glutamine flux through the cellular glutaminase (GA) and 2) paracellular permeability (PP). Because both responses are the result of a decreased glutamate uptake, the present study was designed to determine whether the transport step or resulting fall in cellular glutamate modulates PP. To do so, advantage was taken of the ability of D-glutamate to competitively displace the natural L-isomer yet maintain transporter activity at or even above that normally occurring with L-glutamate. As a consequence cellular L-glutamate would fall while transporter fluxes remained. Accordingly, LLC-PK1-F+ cells were grown to confluent monolayers on porous supports in Dulbecco's modified Eagle's medium containing 50 microM L-glutamate and 1.8 mM L-glutamine with and without 1 mM D-glutamate. After a 90-min exposure to D-glutamate monolayer, L-glutamate content had fallen 38%. D-Glutamate was transported in place of the L-isomer as evidenced by the accumulation of L-glutamate in the media and uptake of the D-isomer. Although GA activation occurs as the result of the fall in cellular L-glutamate, PP did not increase; in fact, it slightly decreased as evidenced by an increased electrical resistance (from 180 +/- 12 to 210 +/- 10 omega x cm2, P < 0.02) and reduction in L-[(14)C]glucose permeability (2.72 +/- 0.75 to 2.28 +/- 0.37%, P = 0.10). Thus glutamate transporter activity and associated ionic fluxes rather than the fall in cellular glutamate and GA activation appear to play the critical role in modulating PP.

ATP-Binding Cassette Transporters↗
PubMed1996

Acid-base homeostasis parallels anabolism in surgically stressed rats treated with GH and IGF-I.

The effect of a standard surgical stress and subsequent total parenteral nutrition (TPN) treatment on systemic acid-base balance was assessed in four groups of rats: TPN controls, TPN coinfused with recombinant human insulin-like growth factor I (rhIGF-I, 800 micrograms/day), TPN with recombinant human growth hormone (rhGH, 800 micrograms in two divided daily sc doses), and combined rhGH plus rhIGF-I (800 + 800 micrograms/day). After the 6-day time course, TPN controls exhibited a systemic metabolic acidosis (HCO3- = 20.4 +/- 0.4 mM) and lost 7 g body wt/6 days. Either growth factor ameliorated the acidosis (rhGH = 22.6 +/- 0.6 and IGF-I = 22.0 +/- 0.5 mM) and promoted weight gain (11 +/- 2 and 10 +/- 3 g/6 days, respectively). Combined growth factor treatment, rhGH+rhIGF-I, restored acid-base balance (HCO3- = 24.7 +/- 0.6 mM) and exhibited an additive effect on weight gain (25 +/- 3 g/6 days). Ammonium and sulfate excretion as indexes of renal acid excretion and systemic sulfuric acid production, respectively, were highest in the TPN control, Growth factors alone reduced sulfuric acid production, whereas combined growth factor treatment reduced acid production and eliminated acid excretion despite elevated renal glutaminase activity. However, renal cortical glutamate content was elevated in the combined growth factor treatment (10.6 +/- 0.7 vs. 7.3 +/- 0.5 rhGH+rhIGF-1 vs. TPN, P < 0.05), consistent with repression of the elevated glutaminase activity. These findings point to an important role for acid-base homeostasis in the anabolic response and are consonant with an additive effect of growth factors, rhGH+rhIGF-I, in correcting the metabolic acidosis associated with surgical stress.

Abdomen↗
PubMed1995

Increased plasma bicarbonate and growth hormone after an oral glutamine load.

An oral glutamine load was administered to nine healthy subjects to determine the effect on plasma glutamine, bicarbonate, and circulating growth hormone concentrations. Two grams glutamine were dissolved in a cola drink and ingested over a 20-min period 45 min after a light breakfast. Forearm venous blood samples were obtained at zero time and at 30-min intervals for 90 min and compared with time controls obtained 1 wk earlier. Eight of nine subjects responded to the oral glutamine load with an increase in plasma glutamine at 30 and 60 min before returning to the control value at 90 min. Ninety minutes after the glutamine administration load both plasma bicarbonate concentration and circulating plasma growth hormone concentration were elevated. These findings demonstrate that a surprisingly small oral glutamine load is capable of elevating alkaline reserves as well as plasma growth hormone.

Administration, Oral↗
PubMed1995

Extracellular glutamate flux regulates intracellular glutaminase activity in LLC-PK1-F+ cells.

The role of extracellular glutamate flux in regulating intracellular glutaminase activity was assessed in confluent monolayers of proximal tubule-like LLC-PK1-F+ cells grown on porous supports. Glutamate is a well-known inhibitor of phosphate-dependent glutaminase (PDG). We hypothesized that, by restricting the flux of glutamate from the extracellular media, cellular level would fall, effecting deinhibition of the cellular glutaminase activity. To test this, cellular glutamate uptake and extracellular production were inhibited for 18 h by the addition of D-aspartate (10 mM) or acivicin (0.7 mM) to both apical and basal media. Inhibiting glutamate flux depressed cellular glutamate content 43 and 41%, respectively. Intracellular relative glutaminase activity, monitored as the breakdown of 14C-radiolabeled glutamine to glutamate, measured over 60 s in the presence of D-aspartate or acivicin showed a 2- to 2.5-fold increase with the fall in cellular glutamate. Interestingly, enhanced glutamine uptake after PDG deinhibition was predominantly expressed on the basal surface. Indeed, measuring glutamine utilization after gamma-glutamyltranspeptidase inhibition over the entire 18-h time course revealed inhibition at the apical surface but relative enhancement of uptake at the basal surface. The increased intracellular glutaminase pathway was also reflected in increased alanine production measured over the 18-h time course, despite the reduction in overall glutamine utilization. These results point to a major role for extracellular glutamate fluxes in regulating cellular glutamine metabolism and suggest that the intracellular pathway may be suppressed under these conditions.

Animals↗